Pascal Neuville
Founder at Peptimimesis SAS
Profile
Pascal Neuville is the founder of Domain Therapeutics SA, which was founded in 2008.
He held the titles of CEO, Director, and Chief Scientific Officer from 2008 to 2024.
He is also the founder of Peptimimesis SAS, which was founded in 2015, and currently serves as Chairman.
Dr. Neuville is currently the Chairman of Axilum Robotics SAS, Director of Mavalon Therapeutics Ltd.
since 2018, and Director of Find Therapeutics.
In the past, he worked as the Head of Research & Development Project at Transgene SA from 2002 to 2008.
He was also a Professor at the University of Geneva and served as the President of Alsace BioValley Association from 2008 to 2010.
Dr. Neuville obtained a doctorate degree from the University of Strasbourg.
Pascal Neuville active positions
| Companies | Position | Start |
|---|---|---|
Axilum Robotics SAS
 Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | Chairman | - |
Peptimimesis SAS
 Peptimimesis SAS BiotechnologyHealth Technology Peptimimesis SAS provides biotechnology research services. Its platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology, and immune diseases. The company was founded by Dominique Bagnard and Pascal Neuville in October 2015 and is headquartered in Strasbourg, France. | Founder | 30/09/2015 |
Find Therapeutics
 Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Director/Board Member | - |
Mavalon Therapeutics Ltd.
 Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Director/Board Member | 30/06/2018 |
Former positions of Pascal Neuville
| Companies | Position | End |
|---|---|---|
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Chief Executive Officer | 07/01/2024 |
Alsace BioValley Association
 Alsace BioValley Association Medical/Nursing ServicesHealth Services Alsace BioValley Association operates as a health innovation center. The private company is based in Illkirch, France. | President | 31/12/2009 |
| TRANSGENE | Corporate Officer/Principal | 31/12/2007 |
| University of Geneva | Corporate Officer/Principal | - |
Training of Pascal Neuville
| University of Strasbourg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Private companies | 6 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Alsace BioValley Association
Alsace BioValley Association Medical/Nursing ServicesHealth Services Alsace BioValley Association operates as a health innovation center. The private company is based in Illkirch, France. | Health Services |
Peptimimesis SAS
Peptimimesis SAS BiotechnologyHealth Technology Peptimimesis SAS provides biotechnology research services. Its platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology, and immune diseases. The company was founded by Dominique Bagnard and Pascal Neuville in October 2015 and is headquartered in Strasbourg, France. | Health Technology |
Mavalon Therapeutics Ltd.
Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Health Technology |
Find Therapeutics
Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France. | Commercial Services |
- Stock Market
- Insiders
- Pascal Neuville